---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-023129"
form_type: "8-K"
ticker: "NAGE"
cik: "0001386570"
company_name: "Niagen Bioscience, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:24:59.021468+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Niagen Bioscience Q1 net sales $30.5M (+38% YoY), net income $5.1M, raises FY2025 outlook

## Summary
- Total net sales of $30.5M, up 38% YoY; gross margin 63.4% (+270 bps).
- Net income of $5.1M ($0.07 EPS) vs net loss of $0.5M in Q1 2024.
- Adjusted EBITDA of $4.9M, up from $0.7M in prior year.
- Raised FY2025 outlook: net sales growth 20-25% (prev ~18%); adj G&A $7-8M.
- Name change to Niagen Bioscience, ticker NAGE effective Mar 19; new patent for NR salt forms.

## SEC filing metadata
- accession: 0001628280-25-023129
- form_type: 8-K
- ticker: NAGE
- cik: 0001386570
- company_name: Niagen Bioscience, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1386570/000162828025023129/0001628280-25-023129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1386570/000162828025023129/cdxc-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-023129
- JSON: https://secwatch.observer/filing/0001628280-25-023129.json
- Plain text: https://secwatch.observer/filing/0001628280-25-023129.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.